PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 203 filers reported holding PDL BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $0 | – | 104 | +20.9% | 0.00% | – |
| Q1 2017 | $0 | – | 86 | -17.3% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 104 | -84.1% | 0.00% | – |
| Q3 2016 | $2,000 | 0.0% | 654 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $2,000 | 0.0% | 654 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $2,000 | 0.0% | 654 | +6.5% | 0.00% | 0.0% |
| Q4 2015 | $2,000 | -33.3% | 614 | +11.6% | 0.00% | 0.0% |
| Q3 2015 | $3,000 | -78.6% | 550 | -72.5% | 0.00% | -75.0% |
| Q1 2015 | $14,000 | -58.8% | 2,000 | -54.2% | 0.00% | -42.9% |
| Q4 2014 | $34,000 | -61.4% | 4,370 | -62.8% | 0.01% | -58.8% |
| Q3 2014 | $88,000 | -22.1% | 11,737 | +0.6% | 0.02% | -19.0% |
| Q2 2014 | $113,000 | +17.7% | 11,666 | +0.6% | 0.02% | +10.5% |
| Q1 2014 | $96,000 | +4.3% | 11,598 | +6.0% | 0.02% | +46.2% |
| Q4 2013 | $92,000 | -57.6% | 10,938 | -59.9% | 0.01% | -61.8% |
| Q3 2013 | $217,000 | +93.8% | 27,258 | +88.3% | 0.03% | +78.9% |
| Q2 2013 | $112,000 | – | 14,476 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SMH CAPITAL ADVISORS INC | 81,713 | $176,000 | 0.39% |
| BRANDES INVESTMENT PARTNERS, LP | 5,465,156 | $11,805,000 | 0.30% |
| Crestline Management, LP | 875,000 | $1,890,000 | 0.30% |
| West Family Investments, Inc. | 539,450 | $1,165,000 | 0.29% |
| WEBER ALAN W | 200,000 | $432,000,000 | 0.19% |
| Zebra Capital Management LLC | 73,910 | $160,000 | 0.18% |
| RBF Capital, LLC | 569,323 | $1,230,000 | 0.14% |
| Leap Investments LP | 69,496 | $150,000 | 0.08% |
| Connor, Clark & Lunn Investment Management Ltd. | 4,387,038 | $9,476,000 | 0.06% |
| CHICAGO EQUITY PARTNERS LLC | 519,315 | $1,122,000 | 0.05% |